

Creating a Multifocal Cornea

PresbyMAX Hybrid after 1 year

Review of over 11000 treatments with PresbyMAX technology in more than 65 centres



Comparison Matrix of the Grand Total


PresbyMAX symmetric is comparable to other techniques (but for us was not enough)


Presbyopic approach	n	Follow-Up	UDVA	UNVA	DCNVA	CDVA	CNVA	Refr.Outc.	Retreat.	Reversal
Monovision	514	6M-5Y	20/20 87%>20/25	J1 90%>J2					17%	5%
Multifocal	234	6M-2Y	20/20 87%>20/25	J4 81%>J3	J5 49%>+2lns	12%<-2lns	11%<-2lns	76%±0.5DS	21%	
LBV	670	1Y	20/17 99%>20/25	J3 91%>J3		0%<-2Ins		88%±0.5DS 86%±0.5DC	19%	
Supracor	169	6M	20/23 58%>20/25	J2-J3 90%>J3		9%<-2Ins	0%<-2lns	54%±0.5DS 46%±0.5DC	13%	
Intracor	189	6M-18M	20/24 77%>20/25	J3 66%>J2	J2	9%<-2Ins	11%<-2lns			
KAMRA	166	6M-4Y	20/17 93%>20/25	J3 73%>J2		5%<-2Ins	5%<-2Ins		1%	6%
PresbyMAX (Symmetric)	892	6M-1Y	20/24 77%>20/25	J1 90%>J2	J3 38%>+2lns	5%<-2lns	3%<-2lns	85%±0.5DS 98%±0.5DC	10%	1%
	1									



SCHWIND PresbyMAX® Symmetric

3-years stability on 30 patients








SCHWIND PresbyMAX® µ-Monovision

Myopic vs. Hyperopic results on 34 patients

Using μ -monovision at 6-months


- No difference could be observed for myopes vs. hyperopes
- 95% reached UDVA 20/25 or better
- Only 5% lost 2 lines but 15% gained 2 or more lines of CDVA
- 90% reached UNVA J4 or better
- 100% reached DCNVA J5 or better
- Only 5% lost 2 lines, 50% gained 2 or more lines of DCNVA

No postoperative differences after myopic vs. hyperopic µmonovision bi-aspheric ablation profile for presbyopic corneal treatments 5






Symmetric (250 patients) vs. μ-monovision (239 patients) vs. hybrid (145 patients)



 μ -monovision 1 letter better than symmetric hybrid 2 letters better than μ -monovision and 3 letters better than symmetric




Symmetric (250 patients) vs. µ-monovision (239 patients) vs. hybrid (145 patients)



 μ -monovision better than symmetric hybrid better than μ -monovision and better than symmetric




Symmetric (250 patients) vs. µ-monovision (239 patients) vs. hybrid (145 patients)



hybrid 1 letter better than $\mu\text{-monovision}$ and 1 letter better than symmetric




Symmetric (250 patients) vs. µ-monovision (239 patients) vs. hybrid (145 patients)



hybrid 1 letter better than µ-monovision and symmetric



Symmetric (250 patients) vs. μ-monovision (239 patients) vs. hybrid (145 patients)






SCHWIND PresbyMAX® (Reversal)

Case report on a PresbyMAX reversal

Before PresbyMAX

After PresbyMAX

After PresbyMAX Reversal



UDVA:20/10020/4020/16Luger MH, Ewering T, Arba-Mosquera S.Nonwavefront-Guided Presby Reversal Treatment Targeting a MonofocalCornea After Bi-aspheric Ablation Profile in a Patient Intolerant to Multifocality.J Refract Surg. 2014 Mar121;30(3):214-6



SCHWIND PresbyMAX® (Reversal)

Case report on a PresbyMAX reversal

Reversal procedure

- Reversal procedures are seldom (1%)
- They can be safely corrected using a non-wavefront-guided presby reversal treatment targeting a monofocal cornea



Comparison Matrix of the Grand Total

PresbyMAX hybrid is for all metrics comparable or superior than the best of the competing technologies

Presbyopic approach	n	Follow-Up	UDVA	UNVA	DCNVA	CDVA	CNVA	Refr.Outc.	Retreat.	Reversal
Monovision	514	6M-5Y	20/20 87%>20/25	J1 90%>J2					17%	5%
Multifocal	234	6M-2Y	20/20 87%>20/25	J4 81%>J3	J5 49%>+2Ins	12%<-2Ins	11%<-2lns	76%±0.5DS	21%	
LBV	670	1Y	20/17 99%>20/25	J3 91%>J3		0%<-2lns		88%±0.5DS 86%±0.5DC	19%	
Supracor	169	6M	20/23 58%>20/25	J2-J3 90%>J3		9%<-2Ins	0%<-2Ins	54%±0.5DS 46%±0.5DC	13%	
KAMRA	166	6M-4Y	20/17 93%>20/25	J3 73%>J2		5%<-2lns	5%<-2lns		1%	6%
PresbyMAX (Symmetric)	892	6M-1Y	20/24 77%>20/25	J1 90%>J2	J3 38%>+2lns	5%<-2lns	3%<-2lns	85%±0.5DS 98%±0.5DC	10%	1%
PresbyMAX (μ-Monovision)	478	6M	20/23 79%>20/25	J1 90%>J2	J3 83%>+2lns	3%<-2lns	2%<-2lns	87%±0.5DS 93%±0.5DC	15%	1%
PresbyMAX (Hybrid)	372	6M	20/21 94%>20/25	J1 95%>J2	J3 92%>+2lns	1%<-2lns	1%<-2lns	89%±0.5DS 88%±0.5DC	10%	1%
	1		1	1	1	1	1	1	1	1



Mean outcomes

	PresbyMAX Hybrid (372 eyes) PreOP PostOP 6M		Myopes (96 eyes) PreOP PostOP 6M		Emmetropes (104 eyes)PreOPPostOP 6M		Hyperopes (172 eyes) Pre0P Post0P 6M	
Age (years) Mean±SD Range	53±6 44 to 70		50±3 44 to 59		52±7 44 to 66		56±7 44 to 70	
DE SEq (D) Mean±SD Range	0.39±2.27 -7.75 to +4.62	-0.04±0.22 -1.00 to +0.75	-2.94±1.79 -7.75 to -0.13	-0.14±0.18 -0.75 to +0.13	0.75±0.46 -0.50 to +1.50	0±0.23 -1.00 to +0.50	2.05±0.71 +0.12 to +4.62	0±0.23 -1.00 to +0.75
NE SEq (D) Mean±SD Range	0.24±2.53 -8.37 to +5.50	-0.64±0.49 -2.75 to +0.25	-3.4±1.93 -8.37 to -0.12	-0.81±0.43 -2.25 to 0.00	0.74±0.47 -0.50 to +1.38	-0.58±0.58 -2.25 to +0.12	1.94±0.9 +0.12 to +5.50	-0.54±0.44 -2.75 to +0.25
Cyl (D) Mean±SD Range	0.53±0.61 0.00 to 3.75	0.17±0.22 0.00 to 1.25	0.9±0.86 0.00 to 3.75	0.2±0.24 0.00 to 1.25	0.47±0.49 0.00 to +3.50	0.18±0.23 0.00 to +1.00	0.35±0.37 0.00 to +2.25	0.14±0.2 0.00 to +1.00
UDVA (20/x) Mean±SD Range	20/66±23 CF to 20/13	20/21±4 20/50 to 20/13	20/200±26 CF to 20/16	20/21±4 20/32 to 20/13	20/27±8 20/80 to 20/13	20/20±4 20/50 to 20/13	20/61±13 20/200 to 20/16	20/22±3 20/32 to 20/13
UNVA (logRAD) Mean±SD Range	0.6±0.3 1.1 to 0.0	0.0±0.1 0.3 to -0.2	0.1±0.2 0.8 to 0.0	0.0±0.1 0.2 to -0.1	0.6±0.2 0.9 to 0.0	0.1±0.1 0.3 to -0.2	0.8±0.2 1.1 to 0.0	0.0±0.1 0.2 to -0.2
CDVA (20/x) Mean±SD Range	20/19±3 20/25 to 20/13	20/19±3 20/25 to 20/13	20/19±3 20/25 to 20/13	20/19±3 20/25 to 20/13	20/18±3 20/20 to 20/13	20/19±3 20/25 to 20/13	20/20±2 20/20 to 20/13	20/20±2 20/25 to 20/13
DCNVA (logRAD) Mean±SD Range	0.5±0.2 0.8 to -0.1	0.1±0.1 0.7 to 0.0	0.4±0.1 0.6 to 0.1	0.1±0.2 0.6 to 0.0	0.4±0.2 0.8 to -0.1	0.1±0.1 0.7 to 0.0	0.6±0.2 0.8 to 0.2	0.1±0.1 0.7 to 0.0
CNVA (logRAD) Mean±SD Range	0.0±0.0 0.1 to -0.3	0.0±0.0 0.1 to -0.2	0.0±0.0 0.0 to -0.1	0.0±0.1 0.1 to -0.2	0.0±0.0 0.0 to -0.2	0.0±0.0 0.1 to -0.1	0.0±0.0 0.1 to -0.3	0.0±0.0 0.1 to -0.1




Benchmark outcomes

Binocular I	Performance (186 patients)	"FDA-like" Benchmarks	PresbyMAX Hybrid	Pass/Fail
Refractive	PostOP astigmatism greater than 2.0 D Deviation from target SEq within 1.0 D Deviation from target SEq within 0.5 D	<5% >75% >50%	0% 98% 76%	$\frac{1}{\sqrt{2}}$
Distance	More than 2 lines loss of CDVA PostOP CDVA worse than 20/40 PostOP UDVA of 20/40 or better	<5% <1% >85%	0% 0% 99%	$\frac{1}{\sqrt{2}}$
Near	More than 2 lines loss of CNVA PostOP CNVA worse than +0.3 logRAD PostOP UNVA of +0.3 logRAD or better	<5% <1% >85%	0% 0% 100%	$\frac{1}{\sqrt{2}}$




Refractive correction on 186 patients






Refractive astigmatism outcomes on 186 patients





SCHWIND PresbyMAX[®] Hybrid


Refractive outcomes on 186 patients



DE 95% within ±0,5D (from emmetropic target) NE 83% within ±0,63D (from -0,8D target)




Safety on 186 patients






UNVA on 186 patients





UDVA on 186 patients





Summary

Widely used

• Over 11000 treatments in more than 65 centres

Near vision recovery is immediate

• From Day1 postop

Good efficacy

• Bottom-line is binocular UDVA 20/25

Based on SphAb

• Pupil dependent

Stable

• Demonstrated for over 3-years with prospects over 8-years

Predictable

• 10-15% retreatment rate; 1% reversal rate

Reversible

Hybrid version with +1,75D planned addition

• All rounder solution



SCHWIND PresbyMAX[®] Hybrid

Summary

Currently the most frequently used variant

Offering the best results

- From Day1 postop
- Compared to other PresbyMAX variants
- Compared to competing technologies

Easy to use - All rounder solution

- Stable
- Predictable
- Reversible
- Little compromises



Thank you very much for your kind attention!

Vielen Dank für Ihre Aufmerksamkeit!

Samuel Arba Mosquera

PhD in Sciences of Vision MSc in Physics, MSc in Environmental Sciences Optical/Visual Researcher, R&D Department

phone: +49 (0) 6027 508 274 fax: +49 (0) 6027 508 208 email: <u>samuel.arba.mosquera@eye-tech.net</u>